Onchocerciasis is an eye and skin disease caused by the parasite Onchocerca volvulus. It causes intense itching and skin rashes, swelling and ultimately severe dermatitis, and damage in the eye can lead to impaired vision and ultimately blindness.
TDR has a long history of research to support the control of this disease, dating back to the partnership with the Onchocerciasis Control Programme that eliminated the mosquito that transmitted the disease in West Africa. TDR research with the African Programme for Onchocerciasis Control (APOC) has demonstrated how community-directed treatment with ivermectin (CDTI) is a sustainable and improved way of controlling the disease, and shows the possibility of eliminating transmission of the parasite.
More recently, research supported the identification of genetic markers of the parasite’s response to ivermectin and evaluating another compound, moxidectin, for its potential to accelerate elimination of onchocerciasis and expand the areas where elimination of transmission is feasible.
- More on onchocerciasis
- More on the history of TDR research on onchocerciasis
- Research profile of moxidectin, a new drug for control and elimination of onchocerciasis, at TDR
- African Programme for Onchocerciasis Control (APOC)
- The Mectizan Donation Program
- A randomized, single-ascending-dose, ivermectin-controlled, double-blind study of moxidectin in Onchocerca volvulus infection.
- The potential impact of moxidectin on onchocerciasis elimination in Africa: an economic evaluation based on the Phase II clinical trial data
- Study evaluating the co-administration of moxidectin and midazolam in healthy subjects
- Study evaluating the effect of high-fat meal on bioavailability and pharmacokinetics of single dose of moxidectin
- Excretion of moxidectin into breast milk and pharmacokinetics in healthy lactating women
- The antiparasitic moxidectin: safety, tolerability, and pharmacokinetics in humans
- Prospects for moxidectin as a new oral treatment for human scabies
- Preclinical study of single-dose moxidectin, a new oral treatment for scabies: efficacy, safety and pharmacokinetics compared to two-dose ivermectin in a porcine model
- Study comparing the relative bioavailability of a liquid and tablet formulation of moxidectin
- Review: Moxidectin and the avermectins: consanguinity but not identity
- Initial results of evaluation of moxidectin in O. ochengi model
- Research for control: the onchocerciasis experience
- Community-directed interventions for major health problems in Africa
Documenting a research partnership model to eliminate visceral leishmaniasis
Reviewing progress on sterile insect technique to control dengue
Lessons learnt on scaling-up measures to reduce dengue mosquito densities
Recycling decreases mosquito densities in Uruguay
TDR at European Congress on Tropical Medicine and International Health
Pooling patient data could improve VL treatment options
Critical research findings for dengue – fostering the arbovirus research agenda